CRSP News and Press, CRISPR Therapeutics AG From 12/25/23

2023-12-25 10:03:02 ET Summary I discuss my investment and trading strategies before and after March 2022. I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. I want to see the Bull Plateau (or Bear-Mark...

2023-12-22 05:27:00 ET Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (NASDAQ: CRSP) this year. The stock is up more than 60% in 2023 after the company earned Food and Drug Administration (FDA) approval for its ...

2023-12-21 13:56:16 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Vertex sickl...

2023-12-21 08:30:00 ET December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP) . On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment for sickle cell disease. It was a monumental decision as it als...

2023-12-21 05:51:00 ET "The thrill of victory and the agony of defeat." That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (NASDAQ: CRSP) and Pfizer (NYSE: PFE) in 20...

2023-12-20 05:00:00 ET CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their blood disorders candidate, exa-cel, and investors bet on ...

2023-12-19 15:38:50 ET Summary FDA approval of bluebird bio's Lyfgenia for SCD is significant, but high cost and black box warning present challenges. Despite revenue growth from Zynteglo and Skysona, bluebird bio struggles with net losses and shareholder dilution. The company...

2023-12-19 05:00:00 ET Investing generally won't make you a millionaire overnight -- and buying just a few stocks usually won't do the trick either. But if you build a portfolio of about 25 solid stocks and hold on to them for a decade, you could see your investing dreams start to come true...

2023-12-18 05:43:43 ET Summary The best performance of the bull plateau is to advance steadily, not to move monotonously, and support for loyal cash cows. The article discusses winners in various categories such as Mega-Cap Group, Large-Cap Group, Small-Cap Group, Top Gains, All T...

2023-12-17 08:45:00 ET Building a better proverbial mousetrap isn't always a necessary condition for the success of a business, but doing so can help. Those corporations that break new ground often end up being handsomely rewarded, as are those investors bold enough to hold shares of these ...